STERIS (STE) Scheduled to Post Quarterly Earnings on Wednesday

STERIS (NYSE:STE - Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of $2.12 per share for the quarter. STERIS has set its FY25 guidance at $9.05-$9.25 EPS and its FY 2025 guidance at 9.050-9.250 EPS.Persons interested in registering for the company's earnings conference call can do so using this link.

STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping analysts' consensus estimates of $1.98 by $0.16. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The firm had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.27 billion. During the same period last year, the company earned $2.00 earnings per share. The business's revenue for the quarter was down .4% on a year-over-year basis. On average, analysts expect STERIS to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

STERIS Stock Performance

Shares of NYSE:STE traded up $0.52 during midday trading on Wednesday, reaching $224.39. 434,571 shares of the company traded hands, compared to its average volume of 474,129. The firm's fifty day moving average price is $234.38 and its two-hundred day moving average price is $226.73. The firm has a market capitalization of $22.13 billion, a price-to-earnings ratio of 55.55 and a beta of 0.84. The company has a quick ratio of 1.49, a current ratio of 2.33 and a debt-to-equity ratio of 0.35. STERIS has a 12 month low of $195.47 and a 12 month high of $248.24.

Insider Buying and Selling

In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the transaction, the chief financial officer now directly owns 42,930 shares of the company's stock, valued at approximately $10,603,710. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of the company's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the sale, the chief financial officer now directly owns 42,930 shares in the company, valued at $10,603,710. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Christopher S. Holland sold 473 shares of STERIS stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $239.68, for a total value of $113,368.64. Following the completion of the transaction, the director now owns 582 shares in the company, valued at approximately $139,493.76. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

STE has been the subject of a number of analyst reports. Needham & Company LLC restated a "hold" rating on shares of STERIS in a research report on Thursday, August 8th. Stephens reaffirmed an "overweight" rating and issued a $260.00 price target on shares of STERIS in a report on Wednesday, August 7th. JMP Securities restated a "market outperform" rating and set a $265.00 target price on shares of STERIS in a research report on Wednesday, August 7th. Piper Sandler upgraded STERIS from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $230.00 to $260.00 in a research report on Thursday, October 24th. Finally, KeyCorp upped their price objective on shares of STERIS from $255.00 to $265.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 3rd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $253.00.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.